
- English
- ePUB (mobile friendly)
- Available on iOS & Android
About this book
In the wake of publicity and congressional attention to drug safety issues, the Food and Drug Administration (FDA) requested the Institute of Medicine assess the drug safety system. The committee reported that a lack of clear regulatory authority, chronic underfunding, organizational problems, and a scarcity of post-approval data about drugs' risks and benefits have hampered the FDA's ability to evaluate and address the safety of prescription drugs after they have reached the market. Noting that resources and therefore efforts to monitor medications' risk"e;benefit profiles taper off after approval, The Future of Drug Safety offers a broad set of recommendations to ensure that consideration of safety extends from before product approval through the entire time the product is marketed and used.
Frequently asked questions
- Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
- Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Information
Table of contents
- COVER PAGE
- THE NATIONAL ACADEMIES
- COMMITTEE ON THE ASSESSMENT OF THE US DRUG SAFETY SYSTEM
- Reviewers
- Preface
- Contents
- Summary
- 1 Introduction
- 2 Natural History of a Drug
- 3 A Culture of Safety
- 4 The Science of Safety
- 5 Regulatory Authorities for Drug Safety
- 6 Communicating About Safety
- 7 Resources for the Drug Safety System
- Appendix A Moving Target: Changes at FDA During the Course of the Study1
- Appendix B Acronyms
- Appendix C PDUFA Performance Goals—All Years
- Appendix D Committee on the Assessment of the US Drug Safety System Meeting Agendas
- Appendix E Summary
- Appendix F Committee Biographies
- Index